PATIENTS

Migraine in the workplace

European survey on migraine in the workplace. Analysis of results and conclusions. The objective of this study is to know the situation of migraine workers within the workplace and compare the situation in the different participating countries. Read de complete document in our Study section About the study of Migraine in the workplace The objective

Migraine in the workplace Read More »

Suggestions for headache care at coronavirus time

Suggestions for headache care at coronavirus time by  The European Headache Federation (EHF) and The European Migraine & Headache Alliance (EMHA) Coronavirus pandemia has completely changed health systems’ organization and priorities. Headache service are heavily affected by those changes. They have been suspended or reduced, to limit social contacts. Patients also would rather stay at home.

Suggestions for headache care at coronavirus time Read More »

New drugs, decades in the making, are providing relief for migraines.

Nancy Baum Lipsitz remembers the night the pain began. She’d had a glass of white wine with a friend and went to bed with a terrible headache. The next day, she still felt horrible, the beginning of what she called a “rolling tide” of near constant migraines and lower level headaches. For three years she

New drugs, decades in the making, are providing relief for migraines. Read More »

YOGA AND MIGRAINE

What Can Yoga Do for Migraine Relief? Yoga can provide more than just physical fitness. It can bring calm and peace to your mind and body, as well as help with ailments such as anxiety, depression, and pain. It isn’t clear exactly how yoga changes the body in this manner, though the parasympathetic nervous system

YOGA AND MIGRAINE Read More »

“Green light” to Lilly’s monoclonal antibody to migraine

Eli Lilly announces that the European Commission (EC) has approved the commercialization of galcanezumab ( Emgality ) as a prophylactic treatment of migraine in adults suffering from at least four days of migraine per month . Galcanezumab is a humanized monoclonal antibody that binds to the peptide related to the calcite gene (CGRP, for its acronym in English) associated with episodes

“Green light” to Lilly’s monoclonal antibody to migraine Read More »

Migraine Association of Ireland

Migraine Awareness Week 2018 MAI held an accredited Health Care Professional Seminar, during which two international speakers presented on Migraine: Diagnosis and Treatment, and the Development of the new Anti-CGRP medication. Prof. Lars Edvinsson and Prof. Allan Purdy, both members of the IHS, followed this up by doing a webinar for members of the Irish

Migraine Association of Ireland Read More »

Scroll to Top
Search
Close this search box.